Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Université de Montréal

$619,650.00

Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies

EF 2021-22

Résumé
Breast cancer is the most common and one of the deadliest cancers affecting women in North America. One group of breast cancers is called the triple-negative breast cancer and comprises highly aggressive tumors. Patients with triple-negative breast cancer exhibit poor outcomes due to absence of long-term response to chemotherapy, which leads to tumor relapse and metastasis. Identification of additional therapies to efficiently treat this group of breast cancers is therefore a priority. One of the main issues with aggressive tumors like the triple-negative breast cancers, is that the cancer cells can change their identity to be able to favor the growth of the tumor and to better survive despite being treated with chemotherapy. The goal of this project is to identify the mechanisms that collaborate together to control how triple negative breast cancer cells change their identify and how these changes in identify help cancer cells to better use different sources of nutrients and resources to generate energy and proliferate. We will also investigate strategies to target these mechanisms in triple-negative breast cancer cells with the goal of preventing tumor growth and progression. The results generated from this project could allow the identification of new biological mechanisms that contribute to the adaptations and progression of tumors. Investigating whether and how these mechanisms can be co-targeted to develop improved pharmacological approaches for the treatment of poor prognosis triple-negative breast cancers.
Programme
Project Grant
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
452533
Name
Deblois Genevieve
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$619,650
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Cancer Therapy; Chromatin Accessibility; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification; Triple-Negative Breast Cancer
Abstract
Breast cancer is the most common and one of the deadliest cancers affecting women in North America. One group of breast cancers is called the triple-negative breast cancer and comprises highly aggressive tumors. Patients with triple-negative breast cancer exhibit poor outcomes due to absence of long-term response to chemotherapy, which leads to tumor relapse and metastasis. Identification of additional therapies to efficiently treat this group of breast cancers is therefore a priority. One of the main issues with aggressive tumors like the triple-negative breast cancers, is that the cancer cells can change their identity to be able to favor the growth of the tumor and to better survive despite being treated with chemotherapy. The goal of this project is to identify the mechanisms that collaborate together to control how triple negative breast cancer cells change their identify and how these changes in identify help cancer cells to better use different sources of nutrients and resources to generate energy and proliferate. We will also investigate strategies to target these mechanisms in triple-negative breast cancer cells with the goal of preventing tumor growth and progression. The results generated from this project could allow the identification of new biological mechanisms that contribute to the adaptations and progression of tumors. Investigating whether and how these mechanisms can be co-targeted to develop improved pharmacological approaches for the treatment of poor prognosis triple-negative breast cancers.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Deblois, Genevieve
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $619,650~ $0~